Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

Increasing access to these effective evidence-based treatments would benefit our society as a whole, not just those impacted ...

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Glucagon-like peptide-1 receptor agonists (GLP-1) drugs are a class of medications used to manage type 2 diabetes and treat obesity. While many drugs in this class are relatively new, researchers are ...

GLP-1 drugs like Ozempic can help kidney transplant patients avoid organ failure and live longer, a new study sugges ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

Multiple studies show GLP-1 agonist drugs can also eliminate a person's penchant for sweets ... What they did find, however, ...